Vion Pharmaceuticals, Inc.

Vion Pharmaceuticals, Inc. (Vion) is a development-stage pharmaceutical company engaged in the development and commercialization of therapeutics for the treatment of cancer. The company has two small molecule anticancer agents in clinical development, which includes Onrigin (Laromustine) and Triapine. It also has two anticancer agents in the preclinical development-stage. The company is headquartered in New Haven, Connecticut, the US.

In February 2009, the company filed a New Drug Application (NDA) for Onrigin with the United States Food and Drug Administration (FDA). In December 2009, Vion Pharmaceuticals, Inc. had voluntarily filed for bankruptcy under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Vion is continuing to operate its business as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.

Street: 
4 Science Park
City: 
New Haven
Postcode: 
06511
Federal State : 
United States
WebSite: 
www.vionpharm.com
Fax: 
1-203-4984211

Company Index Score

Current Index Score Historical Index Score
  • Vion Pharmaceuticals, Inc. currently scores 50 % in the index.
  • Vion Pharmaceuticals, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Vion Pharmaceuticals, Inc. is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets